Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 237-244

  Sharifzadeh, Zahra ^a   Rahbarizadeh, Fatemeh ^b   Shokrgozar, Mohammad A ^a   Ahmadvand, Davoud ^c   Mahboudi, Fereidoun ^a   Jamnani, Fatemeh Rahimi ^a   Moghimi, S Moein ^d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chimeric antigen receptor; Oligoclonal single domain antibodies; TAG 72

Indexed keywords

ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC NANOCONSTRUCTED ANTIGEN RECEPTOR; GLYCOPROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; NANOBODY; TAG 72 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; ARTIODACTYLA; BACTERIOPHAGE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GENE LIBRARY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CAMELIDS, NEW WORLD; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; GENETIC ENGINEERING; GLYCOPROTEINS; HT29 CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, T-CELL; LYMPHOCYTE ACTIVATION; PEPTIDE LIBRARY; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SINGLE-DOMAIN ANTIBODIES; T-LYMPHOCYTES; TRANSFECTION;

CAMELIDAE;

EID: 84878235377     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.010     Document Type: Article

References (46)

1. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
2. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
3. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of " tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
4. Park T.S., Rosenberg S.A., Morgan R.A. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011, 29:550-557.
5. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 1989, 86:10024-10028.
6. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
7. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172:104-113.
8. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
9. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
10. Revets H., De Baetselier P., Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin. Biol. Ther. 2005, 5:111-124.
11. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
12. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986, 46:3118-3124.
13. Hombach A., Heuser C., Sircar R., Tillmann T., Diehl V., Kruis W., Pohl C., Abken H. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997, 113:1163-1170.
14. McGuinness R.P., Ge Y., Patel S.D., Kashmiri S.V., Lee H.S., Hand P.H., Schlom J., Finer M.H., McArthur J.G. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum. Gene Ther. 1999, 10:165-173.
15. Friedmann-Morvinski D., Eshhar Z. Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity. Update Cancer Ther. 2006, 1:25-32.
16. Halapi E. Oligoclonal T cells in human cancer. Med. Oncol. 1998, 15:203-211.
17. Derniame S., Vignaud J.M., Faure G.C., Béné M.C., Massin F. Comparative T-cell oligoclonality in lung, tumor and lymph nodes in human non-small cell lung cancer. Oncol. Rep. 2005, 13:509-515.
18. Heiser A., Maurice M.A., Yancey D.R., Wu N.Z., Dahm P., Pruitt S.K., Boczkowski D., Nair S.K., Ballo M.S., Gilboa E. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 2001, 166:2953.
19. Ahmadvand D., Rasaee M.J., Rahbarizadeh F., Kontermann R.E., Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol. 2009, 46:1814-1823.
20. Beatty J.D., Beatty B.G., Vlahos W.G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J. Immunol. Methods 1987, 100:173-179.
21. Iri-Sofla F.J., Rahbarizadeh F., Ahmadvand D., Rasaee M.J. Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase. Exp. Cell Res. 2011, 317:2630-2641.
22. Khaleghi S., Rahbarizadeh F., Ahmadvand D., Rasaee M.J., Pognonec P. A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int. J. Hematol. 2012, 95:434-444.
23. Jost L., Kirkwood J., Whiteside T. Improved short-and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J. Immunol. Methods 1992, 147:153-165.
24. Maher J., Brentjens R.J., Gunset G., Riviere I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 2002, 20:70-75.
25. Palumbo S.M.L., Memmott R.M., Uribe D.J., Krotova-Khan Y., Hurley L.H., Ebbinghaus S.W. A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids Res. 2008, 36:1755-1769.
26. Wong L.H., Ren H., Williams E., McGhie J., Ahn S., Sim M., Tam A., Earle E., Anderson M.A., Mann J. Histone H3. 3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells. Genome Res. 2009, 19:404-414.
27. Ohuchi N., Gero E., Mori S., Akimoto M., Matoba N., Nishihira T., Hirayama K., Colcher D., Schlom J. Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma. J. Tumor Marker Oncol. 1990, 5:1-10.
28. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., Sah D.W.Y., Stebbing D., Crosley E.J., Hafez I.M. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28:172-176.
29. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9:874-885.
30. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., Cauerhff A., Danquah W., Rissiek B., Scheuplein F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 2009, 198:157-174.
31. Pulè M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 2005, 12:933-941.
32. Marin V., Pizzitola I., Agostoni V., Attianese G.M.P.G., Finney H., Lawson A., Pule M., Rousseau R., Biondi A., Biagi E. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010, 95:2144-2152.
33. Hombach A.A., Abken H. Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 2011, 129:2935-2944.
34. Lamers C.H., Willemsen R., van Elzakker P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., Oosterwijk E., Sleijfer S., Debets R., Gratama J.W. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117:72-82.
35. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., Qian X., James S.E., Raubitschek A., Forman S.J., Gopal A.K., Pagel J.M., Lindgren C.G., Greenberg P.D., Riddell S.R., Press O.W. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
36. Beecham E.J., Ortiz-Pujols S., Junghans R.P. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. J. Immunother. 2000, 23:332-343.
37. Hombach A., Muche J.M., Gerken M., Gellrich S., Heuser C., Pohl C., Sterry W., Abken H. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. Gene Ther. 2001, 8:891-895.
38. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2:256-265.
39. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., De Baetselier P., Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 2002, 98:456-462.
40. Coppieters K., Dreier T., Silence K., de Haard H., Lauwereys M., Casteels P., Beirnaert E., Jonckheere H., Van de Wiele C., Staelens L., Hostens J., Revets H., Remaut E., Elewaut D., Rottiers P. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006, 54:1856-1866.
41. Schumacher T.N. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2002, 2:512-519.
42. Bitton N., Verrier F., Debré P., Gorochov G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur. J. Immunol. 1998, 28:4177-4187.
43. Lanitis E., Poussin M., Hagemann I.S., Coukos G., Sandaltzopoulos R., Scholler N., Powell D.J. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol. Ther. 2011, 20:633-643.
44. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 2007, 25:390-394.
45. Newcombe C., Newcombe A.R. Antibody production: polyclonal-derived biotherapeutics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848:2-7.
46. Sadeqzadeh E., Rahbarizadeh F., Ahmadvand D., Rasaee M.J., Parhamifar L., Moghimi S.M. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Rel. 2011, 156:85-91.